Nodthera Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target the NLRP3 inflammasome pathway for the treatment of chronic inflammatory and neurodegenerative diseases. The company was founded in 2017 and is headquartered in London, UK with operations in Cambridge, Massachusetts[1].
Nodthera's mission is to develop first-in-class small molecule inhibitors of NLRP3, a key protein complex that drives chronic inflammation in numerous diseases including Alzheimer's disease, Parkinson's disease, and inflammatory disorders.
| Drug | Mechanism | Stage | Status |
|---|---|---|---|
| NT-0796 | NLRP3 inflammasome inhibitor | Phase 1/2 | Recruiting |
| NT-0249 | NLRP3 inflammasome inhibitor | Preclinical | IND-enabling |
NT-0796 is a potent, oral, brain-penetrant NLRP3 inflammasome inhibitor being developed for the treatment of Alzheimer's disease. It represents a novel approach targeting neuroinflammation, which is increasingly recognized as a central driver of neurodegenerative processes[2].
The NLRP3 inflammasome is a multi-protein complex that activates pro-inflammatory cytokines (IL-1β, IL-18) in response to various damage-associated molecular patterns (DAMPs). In Alzheimer's disease:
NT-0796 aims to interrupt this cycle by directly inhibiting NLRP3 activation, potentially slowing disease progression[3].
Nodthera is also developing NLRP3 inhibitors for Parkinson's disease, where neuroinflammation similarly plays a critical role in disease progression.
The NLRP3 (NOD-like receptor family pyrin domain containing 3) inflammasome is one of several inflammasome complexes in the body. It is activated by:
Activation leads to:
In the brain, NLRP3 is primarily expressed in microglia, the resident immune cells of the CNS. Chronic NLRP3 activation in microglia contributes to:
Nodthera's approach involves direct inhibition of NLRP3 ATPase activity, which is required for inflammasome assembly and activation. This mechanism differs from:
Nodthera has built a strong patent portfolio around:
Nodthera's NLRP3 inhibitor approach competes with:
| Company | Drug | Stage | Notes |
|---|---|---|---|
| Nodthera | NT-0796 | Phase 1/2 | Brain-penetrant |
| Ionis | IONIS-MAPTRx | Phase 1/2 | Anti-tau ASO |
| INmune Bio | XPro1595 | Phase 2 | TNF inhibitor |
| AL002 (Alector) | TREM2 agonist | Phase 2 | Microglial target |